Following FDA meeting a new phase III trial is planned for Vicineum for the treatment of NMIBC
Following FDA meeting a new phase III trial is planned for Vicineum for the treatment of NMIBC (non-muscle invasive bladder cancer)
After meeting with the FDA, Sesen Bio Inc., plans to conduct an additional Phase III clinical trial for Vicineum for the treatment of NMIBC (non-muscle invasive bladder cancer) in connection with the potential resubmission of a BLA.
The Company plans to request a meeting with the FDA in the coming weeks to align on the remaining outstanding items related to the additional Phase III clinical trial.
Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. For this reason, the activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins